F8-S43-S3
Cat. No.：YN252145
| 产品名称: | F8-S43-S3 |
| CAS No.: | 2719679-31-7 |
| Chemical Name: | (9Z,12Z)-octadeca-9,12-dien-1-yl ((((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate |
| Synonyms: | |
| 分子量: | 766.863401 |
| 分子式: | C39H55N6O8P |
| SMILES: | N#C[C@@]1(C2=CC=C3N2N=CN=C3N)O[C@@H]([C@H]([C@H]1O)O)COP(OC4=CC=CC=C4)(N[C@@H](C)C(OCCCCCCCC/C=C\C/C=C\CCCCC)=O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | MMT5-14 是一种瑞德西韦类似物，对四种SARS-CoV-2变种相比于Remdesivir(HY-104077) 具有更高的抗病毒活性。MMT5-14 抑制 SARS-CoV-2 以及 α，β，γ 和 δ 变种EC50值分别为 0.4，2.5，15.9，1.7 和 5.6 μM。MMT5-14 可用于 COVID-19 的研究。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Hu, H., Traore, M.D.M., Li, R., et al.Optimization of the prodrug moiety of remdesivir to improve lung exposure/selectivity and enhance anti-SARS-CoV-2 activityJ. Med. Chem.65(18),12044-12054(2022)
